NASDAQ:NVNO enVVeno Medical (NVNO) Stock Price, News & Analysis $3.46 +0.14 (+4.22%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About enVVeno Medical Stock (NASDAQ:NVNO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get enVVeno Medical alerts:Sign Up Key Stats Today's Range$3.37▼$3.5150-Day Range$3.05▼$5.5252-Week Range$3.01▼$6.97Volume252,688 shsAverage Volume107,405 shsMarket Capitalization$46.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewenVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Read More… The most serious warning of my career (Ad)With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. Click here now to grab your seat now. enVVeno Medical Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks32nd Percentile Overall ScoreNVNO MarketRank™: enVVeno Medical scored higher than 32% of companies evaluated by MarketBeat, and ranked 845th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for enVVeno Medical.Read more about enVVeno Medical's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for enVVeno Medical are expected to grow in the coming year, from ($1.30) to ($1.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of enVVeno Medical is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of enVVeno Medical is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioenVVeno Medical has a P/B Ratio of 1.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.14% of the float of enVVeno Medical has been sold short.Short Interest Ratio / Days to CoverenVVeno Medical has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in enVVeno Medical has recently decreased by 28.02%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldenVVeno Medical does not currently pay a dividend.Dividend GrowthenVVeno Medical does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.14% of the float of enVVeno Medical has been sold short.Short Interest Ratio / Days to CoverenVVeno Medical has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in enVVeno Medical has recently decreased by 28.02%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment1.29 News SentimentenVVeno Medical has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for enVVeno Medical this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for NVNO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added enVVeno Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, enVVeno Medical insiders have not sold or bought any company stock.Percentage Held by Insiders17.00% of the stock of enVVeno Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.71% of the stock of enVVeno Medical is held by institutions.Read more about enVVeno Medical's insider trading history. Receive NVNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for enVVeno Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address NVNO Stock News HeadlinesenVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)October 28 at 9:48 PM | finance.yahoo.comAVITA Medical Headed For Its Most Important Report, I'm Extremely BullishOctober 2, 2024 | seekingalpha.comElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 29, 2024 | Porter & Company (Ad)BioMedNewsBreaks — enVVeno Medical Corporation (NASDAQ: NVNO) Announces Pricing of $15M Underwritten Public OfferingOctober 1, 2024 | msn.comenVVeno Medical (NASDAQ:NVNO) Stock Quotes, Forecast and News SummarySeptember 28, 2024 | benzinga.comCrude Oil Rises; Onconetix Shares Spike HigherSeptember 27, 2024 | msn.comCassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market SessionSeptember 27, 2024 | msn.comEnVVeno Medical Announces Pricing Of Public Offering - Quick FactsSeptember 27, 2024 | markets.businessinsider.comSee More Headlines NVNO Stock Analysis - Frequently Asked Questions How have NVNO shares performed this year? enVVeno Medical's stock was trading at $5.14 at the beginning of the year. Since then, NVNO shares have decreased by 32.7% and is now trading at $3.46. View the best growth stocks for 2024 here. How were enVVeno Medical's earnings last quarter? enVVeno Medical Corporation (NASDAQ:NVNO) announced its earnings results on Wednesday, July, 31st. The company reported ($0.31) earnings per share (EPS) for the quarter. How do I buy shares of enVVeno Medical? Shares of NVNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of enVVeno Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that enVVeno Medical investors own include Bionano Genomics (BNGO), VBI Vaccines (VBIV), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Amarin (AMRN), Coherus BioSciences (CHRS) and Exelixis (EXEL). Company Calendar Last Earnings7/31/2024Today10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NVNO CUSIPN/A CIK1661053 Webwww.hancockjaffe.com Phone(949) 261-2900Fax949-261-2992Employees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,520,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-54.24% Return on Assets-50.69% Debt Debt-to-Equity RatioN/A Current Ratio23.33 Quick Ratio23.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.47 per share Price / Book1.00Miscellaneous Outstanding Shares13,330,000Free Float11,064,000Market Cap$46.12 million OptionableOptionable Beta1.21 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:NVNO) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enVVeno Medical Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share enVVeno Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.